These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18267248)

  • 21. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Lundblad M
    J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms of l-DOPA-induced dyskinesia.
    Fisone G; Bezard E
    Int Rev Neurobiol; 2011; 98():95-122. PubMed ID: 21907084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
    Konitsiotis S; Tsironis C
    Behav Brain Res; 2006 Jun; 170(2):337-41. PubMed ID: 16621050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
    Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
    Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
    Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH; Huot P; Damude S; Fox SH; Jones SW; Rusche JR; Brotchie JM
    Parkinsonism Relat Disord; 2013 Feb; 19(2):260-4. PubMed ID: 22901956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.
    Deogaonkar M; Subramanian T
    Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pathophysiology and therapy of L-Dopa-induced dyskinesia].
    Hadj Tahar A; Bézard E; Grondin R; Gross CE; Bédard PJ
    Rev Neurol (Paris); 2003 Dec; 159(12):1125-42. PubMed ID: 14978413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical approach to l-dopa-induced dyskinesias.
    Sankar T; Lozano AM
    Int Rev Neurobiol; 2011; 98():151-71. PubMed ID: 21907086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
    Guan Q; Zhan Q; He Y; Tan L
    Neurosci Lett; 2007 Oct; 426(1):64-8. PubMed ID: 17884291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
    Grégoire L; Rassoulpour A; Guidetti P; Samadi P; Bédard PJ; Izzo E; Schwarcz R; Di Paolo T
    Behav Brain Res; 2008 Jan; 186(2):161-7. PubMed ID: 17868931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
    Lane EL; Vercammen L; Cenci MA; Brundin P
    Exp Neurol; 2009 Sep; 219(1):355-8. PubMed ID: 19393238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
    Dekundy A; Lundblad M; Danysz W; Cenci MA
    Behav Brain Res; 2007 Apr; 179(1):76-89. PubMed ID: 17306893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
    Kis B; Hedrich K; Kann M; Schwinger E; Kömpf D; Klein C; Pramstaller PP
    Neurology; 2005 Sep; 65(5):761. PubMed ID: 16157916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.